COST-ANALYSIS FOR TOXICITY MANAGEMENT IN ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER: NIVOLUMAB VS DOCETAXEL

被引：3

作者：

Ortega-Joaquin, N. ^{[1
]}

Echave, M. ^{[2
]}

Oyaguez, I ^{[3
]}

Garrido, P. ^{[4
]}

Felip, E. ^{[5
]}

Trigo, J. ^{[6
]}

Filori, M. ^{[7
]}

Gonzalez Garcia, P. ^{[7
]}

机构：

[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain

[2] Pharmacoecon & Outcomes Res Iberia, Pozuelo De Alarcon, Madrid, Spain

[3] Pharmacoecon & Outcomes Res Iberia, Pozuelo De Alarcon, Spain

[4] Hosp Univ Ramon & Cajal, Madrid, Spain

[5] Hosp Univ Vall dHebron, Barcelona, Spain

[6] Hosp Univ Virgen de la Victoria, Malaga, Spain

[7] Bristol Myers Squibb, Madrid, Spain

来源：

关键词：

D O I：

10.1016/j.jval.2016.09.2150

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN77

引用

页码：A722 / A722

页数：1